CD20 Protein, Human, Recombinant (His & Avi), Biotinylated

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in E. coli expression system with C-His-Avi tag. The predicted molecular weight is 16.8 kDa and the accession number is P11836-1.

规格	价格/CNY		数量
100 μg	￥ 5,180	5日内发货
500 μg	￥ 20,700	5日内发货
1 mg	￥ 34,600	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 5,180

5日内发货

500 μg

￥ 20,700

5日内发货

1 mg

￥ 34,600

5日内发货

生物活性

Immobilized Biotinylated Human CD20, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-CD20 Antibody, hFc Tag with the EC50 of 87.3ng/ml determined by ELISA.

产品描述

种属	Human
表达系统	E. coli
标签	C-His-Avi
蛋白编号	P11836-1
别名	MS4A-1, CD20, B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 11, Leukocyte surface antigen Leu-16, Bp35, MS4A1
蛋白构建	Ile141-Ser188
蛋白纯度	> 95% as determined by Tris-Bis PAGE
分子量	16.8 kDa (predicted) same as Tris-Bis PAGE result.

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in 20 mM PB , 10% Glycerol (pH 7.0).
存储	It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.